DexCom, Inc.(DXCM)
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Latest News & Analysis
DexCom (DXCM) Navigates Innovation Amid Legal Scrutiny
DexCom navigates legal scrutiny and product innovation, launching its G7 15-day sensor while maintaining strong financial growth and market leadership in CGM technology.
DexCom DXCM: Legal Scrutiny Meets G7 Innovation in Mid-2025
DexCom navigates legal challenges and product launches, including the G7, impacting its market position and investor sentiment in mid-2025.
DexCom (DXCM): G7 FDA Clearance Amid Shareholder Investigations
DexCom (DXCM) balances the strategic boost from its G7 15-day CGM FDA clearance with the impact of ongoing shareholder investigations.
DexCom (DXCM): FDA Warning, Nanowear Partnership, and Market Expansion
DexCom (DXCM) faces FDA scrutiny, partners with Nanowear, and expands CGM coverage. A comprehensive look at recent developments and their impact on investors.
DexCom (DXCM): Navigating FDA Scrutiny, Type 2 Diabetes Market, and Competitive Landscape
DexCom (DXCM) navigates FDA scrutiny, targets Type 2 diabetes market amid CGM competition. Key developments and financial analysis included.
DexCom (DXCM): FDA Hurdles, European Expansion, CGM Innovation
DexCom (DXCM) navigates FDA hurdles, expands in Europe, and innovates CGM technology. Analysis of financial performance, market dynamics, and strategic initiatives.
DexCom (DXCM): Navigating Regulatory Scrutiny and Market Competition
DexCom faces FDA scrutiny amid CGM market competition. Analysis of regulatory challenges, competitive landscape, and financial resilience.
DexCom (DXCM): FDA Warning, Competition, and Market Outlook
Analysis of DexCom's challenges and opportunities in the CGM market, including an FDA warning letter, competitive pressures, and growth prospects.
DexCom Under Scrutiny: FDA Warning Letter, Market Impact, Growth
DexCom (DXCM) faces FDA scrutiny, market impact, and strategic growth in diabetes care. Gain insights into their response, competition, and AI integration.
DexCom, Inc. - Industry Impact and Market Trends Analysis
DexCom, Inc. navigates a dynamic healthcare landscape with AI-driven CGM technology. Revenue growth faces margin pressures amid competition and market volatility.
DexCom (DXCM): Q4 Performance, Stelo Launch, and the Future of CGM
DexCom's Q4 results show revenue growth but an earnings miss. Stelo's launch and AI integration are key. Analyst sentiment is cautiously optimistic amid competition.
DexCom (DXCM) Analysis: CGM Market, Stelo Launch, and Future Growth
DexCom (DXCM) navigates the competitive CGM market with mixed Q4 results, focusing on innovation and strategic partnerships for future growth. Stelo OTC CGM launch is key.
DexCom (DXCM): Navigating Competition and Innovation
A comprehensive analysis of DexCom (DXCM), covering Q4 2024 performance, competition, GLP-1 impacts, AI, global expansion, and analyst views. Key takeaways for investors and analysts.
DexCom CGM Market Analysis: Growth, Competition, and Innovation (DXCM)
DexCom (DXCM) Q4 2024 saw +8.00% revenue growth with an EPS miss amid competitive pressures and global expansion. Cautious optimism drives future strategies.
Dexcom Q4 2024 Earnings: Analyzing CGM Market Trends
Dexcom's Q4 2024 performance shows revenue growth but an EPS miss. This report analyzes the CGM market trends, competition, and strategic initiatives.
Dexcom Q4 2024: Revenue Up, Earnings Down, What's Next?
An in-depth analysis reveals Dexcom's Q4 2024 revenue growth, earnings challenges, competitive pressures, and strategic innovation.